An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825 Article

cited authors

  • Gittleman, Haley; Lim, Daniel; Kattan, Michael W; Chakravarti, Arnab; Gilbert, Mark R; Lassman, Andrew B; Lo, Simon S; Machtay, Mitchell; Sloan, Andrew E; Sulman, Erik P; Tian, Devin; Vogelbaum, Michael A; Wang, Tony JC; Penas-Prado, Marta; Youssef, Emad; Blumenthal, Deborah T; Zhang, Peixin; Mehta, Minesh P; Barnholtz-Sloan, Jill S

fiu authors

publication date

  • May 1, 2017

keywords

  • ADJUVANT TEMOZOLOMIDE
  • BRAIN
  • CONCOMITANT
  • Clinical Neurology
  • EORTC
  • Life Sciences & Biomedicine
  • MULTIFORME
  • NCIC TRIAL
  • NRG Oncology
  • Neurosciences & Neurology
  • Oncology
  • PROGNOSIS
  • PROMOTER METHYLATION
  • RADIOTHERAPY
  • RANDOMIZED PHASE-III
  • RTOG
  • Science & Technology
  • glioblastoma
  • nomogram
  • survival

Digital Object Identifier (DOI)

start page

  • 669

end page

  • 677

volume

  • 19

issue

  • 5